Anti-acetylcholine receptor antibody
EstablishedAnti-AChR antibody is the primary diagnostic marker for myasthenia gravis.
This antibody attacks the connection between nerves and muscles, causing myasthenia gravis. A positive test confirms the diagnosis for most patients, but the antibody level doesn't reliably track how well someone is doing, so doctors watch symptoms, not just the number.
Anti-acetylcholine receptor (AChR) antibodies target receptors at the neuromuscular junction and are the primary diagnostic marker for myasthenia gravis (MG), an autoimmune disorder causing fluctuating muscle weakness.
Positive AChR antibodies confirm MG in about 80% of generalized cases; the remaining ~10% of "seronegative" patients may instead have anti-MuSK or anti-LRP4 antibodies, and roughly 10% remain antibody-negative on all current tests.
Measured via radioimmunoassay (gold standard) or cell-based assays; clustered cell-based assays are gaining use for detecting seronegative cases missed by standard testing.
Antibody titer is not a reliable pharmacodynamic biomarker — studies show weak-to-no correlation between titer changes and individual symptom severity, so clinicians should not rely on titer trends alone to judge treatment response.
Confirms diagnosis in ~80% of generalized MG; titer level does not reliably track disease severity.
- Lee, I., & Sanders, D. (2021). Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic biomarker for myasthenia gravis. Muscle & Nerve.